| Bardia Nemati, MD | |
|
731 Walker Rd # E1, Great Falls, VA 22066-2834 | |
| (818) 966-3542 | |
| Not Available |
| Full Name | Bardia Nemati |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Experience | 33 Years |
| Location | 731 Walker Rd # E1, Great Falls, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104389337 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 0101270346 (Virginia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tu Family Medical And Vision Clinic Llc | 1456744473 | 3 |
News Archive
BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the first subject had been dosed in the Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2. The Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and will involve up to 42 already identified subjects.
The Globe and Mail writes that "[w]hen India announced in 2007 that it had 2.3 million people living with HIV, rather than the 5.7 million reported the year before, the government first attributed much of the change to better data collection. Many in the AIDS field were skeptical."
Imagine being diagnosed with one of the most rare and aggressive forms of breast cancer, given a five percent chance to live and told having children will never be an option. Southern California local Kommah McDowell was told just that— and then she went to City of Hope.
Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
An international team of authors has published a special report in The New England Journal of Medicine titled 'SARS-CoV-2 Variants and Vaccines', which presents global strategies for the possible escape from vaccine-elicited immunity.
› Verified 7 days ago
| Entity Name | Majestic Medical Association Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598347924 PECOS PAC ID: 7113325218 Enrollment ID: O20211108001718 |
News Archive
BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the first subject had been dosed in the Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2. The Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and will involve up to 42 already identified subjects.
The Globe and Mail writes that "[w]hen India announced in 2007 that it had 2.3 million people living with HIV, rather than the 5.7 million reported the year before, the government first attributed much of the change to better data collection. Many in the AIDS field were skeptical."
Imagine being diagnosed with one of the most rare and aggressive forms of breast cancer, given a five percent chance to live and told having children will never be an option. Southern California local Kommah McDowell was told just that— and then she went to City of Hope.
Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
An international team of authors has published a special report in The New England Journal of Medicine titled 'SARS-CoV-2 Variants and Vaccines', which presents global strategies for the possible escape from vaccine-elicited immunity.
› Verified 7 days ago
| Entity Name | Tu Family Medical And Vision Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417617465 PECOS PAC ID: 1456744473 Enrollment ID: O20220215000375 |
News Archive
BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the first subject had been dosed in the Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2. The Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and will involve up to 42 already identified subjects.
The Globe and Mail writes that "[w]hen India announced in 2007 that it had 2.3 million people living with HIV, rather than the 5.7 million reported the year before, the government first attributed much of the change to better data collection. Many in the AIDS field were skeptical."
Imagine being diagnosed with one of the most rare and aggressive forms of breast cancer, given a five percent chance to live and told having children will never be an option. Southern California local Kommah McDowell was told just that— and then she went to City of Hope.
Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
An international team of authors has published a special report in The New England Journal of Medicine titled 'SARS-CoV-2 Variants and Vaccines', which presents global strategies for the possible escape from vaccine-elicited immunity.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bardia Nemati, MD 731 Walker Rd # E1, Great Falls, VA 22066-2834 Ph: (818) 966-3542 | Bardia Nemati, MD 731 Walker Rd # E1, Great Falls, VA 22066-2834 Ph: (818) 966-3542 |
News Archive
BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the first subject had been dosed in the Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2. The Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and will involve up to 42 already identified subjects.
The Globe and Mail writes that "[w]hen India announced in 2007 that it had 2.3 million people living with HIV, rather than the 5.7 million reported the year before, the government first attributed much of the change to better data collection. Many in the AIDS field were skeptical."
Imagine being diagnosed with one of the most rare and aggressive forms of breast cancer, given a five percent chance to live and told having children will never be an option. Southern California local Kommah McDowell was told just that— and then she went to City of Hope.
Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
An international team of authors has published a special report in The New England Journal of Medicine titled 'SARS-CoV-2 Variants and Vaccines', which presents global strategies for the possible escape from vaccine-elicited immunity.
› Verified 7 days ago